These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 16820980

  • 1. The role of substance P in stress and anxiety responses.
    Ebner K, Singewald N.
    Amino Acids; 2006 Oct; 31(3):251-72. PubMed ID: 16820980
    [Abstract] [Full Text] [Related]

  • 2. Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry.
    Ebner K, Muigg P, Singewald G, Singewald N.
    Ann N Y Acad Sci; 2008 Nov; 1144():61-73. PubMed ID: 19076365
    [Abstract] [Full Text] [Related]

  • 3. Involvement of NK1 receptors in metabolic stress markers after the central administration of substance P.
    Mello DM, Marcinichen DR, Madruga D, Branco R, Paschoalini MA, De Lima TC.
    Behav Brain Res; 2007 Aug 06; 181(2):232-8. PubMed ID: 17540463
    [Abstract] [Full Text] [Related]

  • 4. Neurobiology of substance P and the NK1 receptor.
    Mantyh PW.
    J Clin Psychiatry; 2002 Aug 06; 63 Suppl 11():6-10. PubMed ID: 12562137
    [Abstract] [Full Text] [Related]

  • 5. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats.
    Ebner K, Rupniak NM, Saria A, Singewald N.
    Proc Natl Acad Sci U S A; 2004 Mar 23; 101(12):4280-5. PubMed ID: 15024126
    [Abstract] [Full Text] [Related]

  • 6. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, Cuomo V.
    Int Rev Neurobiol; 2009 Mar 23; 85():57-72. PubMed ID: 19607961
    [Abstract] [Full Text] [Related]

  • 7. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.
    Ressler KJ, Nemeroff CB.
    Depress Anxiety; 2000 Mar 23; 12 Suppl 1():2-19. PubMed ID: 11098410
    [Abstract] [Full Text] [Related]

  • 8. Potential therapeutic targets for neurokinin-1 receptor antagonists.
    Duffy RA.
    Expert Opin Emerg Drugs; 2004 May 23; 9(1):9-21. PubMed ID: 15155133
    [Abstract] [Full Text] [Related]

  • 9. Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1).
    Santarelli L, Gobbi G, Blier P, Hen R.
    J Clin Psychiatry; 2002 May 23; 63 Suppl 11():11-7. PubMed ID: 12562138
    [Abstract] [Full Text] [Related]

  • 10. Anxiolytic-like effects of substance P administration into the dorsal, but not ventral, hippocampus and its influence on serotonin.
    Carvalho MC, Masson S, Brandão ML, de Souza Silva MA.
    Peptides; 2008 Jul 23; 29(7):1191-200. PubMed ID: 18490080
    [Abstract] [Full Text] [Related]

  • 11. Interactions between NPY and CRF in the amygdala to regulate emotionality.
    Sajdyk TJ, Shekhar A, Gehlert DR.
    Neuropeptides; 2004 Aug 23; 38(4):225-34. PubMed ID: 15337374
    [Abstract] [Full Text] [Related]

  • 12. Neurokinin-1 receptor deletion modulates behavioural and neurochemical alterations in an animal model of depression.
    Roche M, Kerr DM, Hunt SP, Kelly JP.
    Behav Brain Res; 2012 Mar 01; 228(1):91-8. PubMed ID: 22155476
    [Abstract] [Full Text] [Related]

  • 13. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
    Herpfer I, Lieb K.
    CNS Drugs; 2005 Mar 01; 19(4):275-93. PubMed ID: 15813642
    [Abstract] [Full Text] [Related]

  • 14. Analysis of the anxiolytic-like effect of TRH and the response of amygdalar TRHergic neurons in anxiety.
    Gutiérrez-Mariscal M, de Gortari P, López-Rubalcava C, Martínez A, Joseph-Bravo P.
    Psychoneuroendocrinology; 2008 Feb 01; 33(2):198-213. PubMed ID: 18079066
    [Abstract] [Full Text] [Related]

  • 15. Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex.
    Guiard BP, Guilloux JP, Reperant C, Hunt SP, Toth M, Gardier AM.
    Mol Pharmacol; 2007 Dec 01; 72(6):1411-8. PubMed ID: 17890358
    [Abstract] [Full Text] [Related]

  • 16. Early life influences on life-long patterns of behavior and health.
    McEwen BS.
    Ment Retard Dev Disabil Res Rev; 2003 Dec 01; 9(3):149-54. PubMed ID: 12953293
    [Abstract] [Full Text] [Related]

  • 17. Substance P: A neuropeptide involved in the psychopathology of anxiety disorders.
    Iftikhar K, Siddiq A, Baig SG, Zehra S.
    Neuropeptides; 2020 Feb 01; 79():101993. PubMed ID: 31735376
    [Abstract] [Full Text] [Related]

  • 18. [Peptides and anxiety].
    Dantzer R.
    Encephale; 1983 Feb 01; 9(4 Suppl 2):177B-182B. PubMed ID: 6144513
    [Abstract] [Full Text] [Related]

  • 19. Modulation of anxiety in rats evaluated in the elevated T-maze: evidence of the relationship between substance P and diazepam.
    Duzzioni M, Calixto AV, Duarte FS, De Lima TC.
    Behav Brain Res; 2008 Feb 11; 187(1):140-5. PubMed ID: 17963853
    [Abstract] [Full Text] [Related]

  • 20. The NPY system in stress, anxiety and depression.
    Heilig M.
    Neuropeptides; 2004 Aug 11; 38(4):213-24. PubMed ID: 15337373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.